Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) FCF Margin (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of FCF Margin data on record, last reported at 19170.41% in Q3 2025.

  • For Q3 2025, FCF Margin fell 1153583.0% year-over-year to 19170.41%; the TTM value through Sep 2025 reached 7741.22%, down 404698.0%, while the annual FY2024 figure was 3178.6%, 805517.0% up from the prior year.
  • FCF Margin reached 19170.41% in Q3 2025 per BTAI's latest filing, down from 10479.17% in the prior quarter.
  • Across five years, FCF Margin topped out at 464757.14% in Q1 2022 and bottomed at 25414.08% in Q1 2023.
  • Average FCF Margin over 4 years is 23067.76%, with a median of 7168.45% recorded in 2025.
  • Peak YoY movement for FCF Margin: crashed -49017122bps in 2023, then surged 2237181bps in 2024.
  • A 4-year view of FCF Margin shows it stood at 16234.87% in 2022, then skyrocketed by 56bps to 7144.41% in 2023, then skyrocketed by 43bps to 4046.17% in 2024, then plummeted by -374bps to 19170.41% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 19170.41% in Q3 2025, 10479.17% in Q2 2025, and 7168.45% in Q1 2025.